Treatment of neuromyelitis optica: Review and recommendations

Treatment of neuromyelitis optica: Review and recommendations

Pokaż inne wersje (1)

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to tr...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D, Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository
Format:	Journal article
Język:	English
Wydane:	Elsevier 2012

Podobne zapisy

Treatment of Neuromyelitis Optica: Review and Recommendations.
od: Kimbrough, D, i wsp.
Wydane: (2012)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, i wsp.
Wydane: (2013)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
od: Fujihara, K, i wsp.
Wydane: (2014)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, i wsp.
Wydane: (2011)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
od: Kim, W, i wsp.
Wydane: (2012)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, i wsp.
Wydane: (2019)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, i wsp.
Wydane: (2012)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, i wsp.
Wydane: (2012)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i wsp.
Wydane: (2015)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
od: Nour, M, i wsp.
Wydane: (2014)

The borderland of neuromyelitis optica.
od: Matthews, L, i wsp.
Wydane: (2009)

Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies
od: Sato, D, i wsp.
Wydane: (2013)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
od: Sato, D, i wsp.
Wydane: (2014)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, i wsp.
Wydane: (2014)

Seasonal pattern of variation in neuromyelitis optica relapses
od: Elsone, L, i wsp.
Wydane: (2012)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
od: Viegas, S, i wsp.
Wydane: (2009)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
od: Leite, M, i wsp.
Wydane: (2012)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
od: Luppe, S, i wsp.
Wydane: (2012)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, i wsp.
Wydane: (2008)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
od: Downer, J, i wsp.
Wydane: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
od: Downer, J, i wsp.
Wydane: (2012)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Nour, M, i wsp.
Wydane: (2015)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
od: Mealy, M, i wsp.
Wydane: (2014)

Racial differences in neuromyelitis optica spectrum disorder
od: Kim, S, i wsp.
Wydane: (2018)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2013)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
od: Tackley, G, i wsp.
Wydane: (2016)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
od: Kitley, J, i wsp.
Wydane: (2012)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
od: Kitley, J, i wsp.
Wydane: (2014)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
od: Waters, P, i wsp.
Wydane: (2016)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
od: Kitley, J, i wsp.
Wydane: (2014)

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, i wsp.
Wydane: (2007)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
od: Palace, J, i wsp.
Wydane: (2010)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
od: Sedani, S, i wsp.
Wydane: (2012)

A mathematical model of cellular swelling in Neuromyelitis optica
od: Laranjeira, S, i wsp.
Wydane: (2017)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
od: Kitley, J, i wsp.
Wydane: (2012)

CAN MRI BE USED AS A DIAGNOSTIC TOOL IN NEUROMYELITIS OPTICA SPECTRUM DISORDER?
od: Matthews, L, i wsp.
Wydane: (2012)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
od: Paul, F, i wsp.
Wydane: (2007)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
od: George, J, i wsp.
Wydane: (2012)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
od: Absoud, M, i wsp.
Wydane: (2014)